{"prompt": "['Trelagliptin-4002', 'Page 19 0f 66', 'Version 2.0', 'July 5,2017', 'controlled by diet/exercise therapy, comparing the \"weekly-dosing\" product with \"daily-dosing\"', 'products, using the Diabetes Therapy-Related QOL (DTR-QOL) Questionnaire.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 20 of 66', 'Version 2.0', 'July 5,10', '5.0', 'STUDY OBJECTIVES AND ENDPOINTS', '5.1', 'Objectives', 'The objective is to assess the reduction in treatment burden during 12 weeks of trelagliptin', 'administration in patients with type 2 diabetes on diet and exercise therapy only.', '5.2', 'Definition of endpoints', '5.2.1', 'Primary endpoints', 'Change from baseline (Week 0) in total score for all question items in the DTR-QOL Questionnaire', 'at the end of the treatment period (Week 12) .', '5.2.2 Secondary endpoints', '5.2.2.1 Efficacy assessment:', 'Changes in the total score for each factor provided through the DTR-QOL Questionnaire', '[Factor 1: Burden on social activities and daily activities (13 questions in all), Factor 2: Anxiety', 'and dissatisfaction with treatment (8 questions in all), Factor 3: Hypoglycemia (4 questions in', 'all) and Factor 4: Treatment satisfaction (4 questions in all)] at each assessment time point.', 'Change in the total score for all questions in the DTR-QOL Questionnaire at each assessment', 'time point.', 'Change in the total score for treatment satisfaction in the Diabetes Treatment Satisfaction', 'Questionnaire (DTSQ) at each assessment time point.', 'Changes in the total scores for all questions in the DTR-QOL Questionnaire and the total scores', 'for treatment satisfaction in the DTSQ, stratified by the following factors at the start of the', 'treatment period (Week 0) within each treatment group.', 'Use of medication for treatment of comorbidities', 'Number of daily doses of medication for treatment of comorbidities (<2 times or >2 times)', 'Total number of daily tablets of medications for treatment of comorbidities (<2tablets or', '>2 tablets)', 'Number of doses of the study drug or comparative drug (once weekly, once daily or twice', 'daily)', 'Changes in the score per question in the DTR-QOL Questionnaire at each assessment time', 'point.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 21 of 66', 'Version 2.0', 'July 5,10', 'Changes in the score per question in the DTSQ at each assessment time point.', '5.2.2.2 Safety endpoints', 'Adverse events', 'Incidence of hypoglycemia', 'Hospitalization for type 2 diabetes (duration and number, excluding educational', 'hospitalization without worsening of diabetes)', '5.2.3 Other Enppoints', 'Laboratory tests [HbA1c, fasting blood glucose, fasting insulin, fasting glucagon, glycoalbumin,', '1,5-AG, serum creatinine, urinary 8-OHdG (using a correction value of uric creatinine', '(8-OHdG/creatinine)) and urinary creatinine]', 'Treatment compliance', 'The Basic Information on Study Subject (Your Basic Profile)', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}